SPARCO Nigeria Site: Conducts Hemo Type SC™ Trial

12 Jan 2018 - 05:30

HemoTypeSC™, is a novel rapid point of care test that uses a lateral flow immunoassay method to detect the presence of HbA, HbS, and HbC with monoclonal antibodies that have very low limits of detection for HbA, HbS, and HbC antigens. These antibodies are blind to HbF, and so even newborns with elevated HbF and low levels of HbA or HbS will be accurately diagnosed. Developed by Silver Lake Corporation, California, USA, HemoTypeSC™ was designed to cater for limited-resource settings and is therefore rapid and affordable. The SPARCO Nigeria Site coordinated an implementation trial of this diagnostic test by Silver Lake Corporation in primary health care centres in the six geopolitical regions across Nigeria.